Does SUPN pay a dividend?

The cached stock data on this page does not show a positive dividend yield for SUPN. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does SUPN stock do?

Biopharmaceutical firm targeting central nervous system (CNS) disorders through commercialized specialty products and internal pipeline development.

What is SUPN stock's price target?

This cached page does not contain a precise model fair value for SUPN.

The TradeMates model verdict for SUPN is HOLD with an investment score of 49/100. Treat this as a model signal to review, not a personal buy recommendation.

Is SUPN a good dividend stock?

SUPN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

SUPN (SUPN) Stock Analysis

Q: Is SUPN stock a good investment?

The cached TradeMates AI model rates SUPN as HOLD with an investment score of 49/100. The model views Supernus Pharmaceuticals as a HOLD, balancing long-term product ramp-up in ADHD (Qelbree) against near-term margin compression and generic erosion of legacy drugs. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Qelbree-driven top-line growth is offset by operating losses and Trokendi XR patent cliff drag — keeping valuation capped near 52-week lows.

Investment score: 49/100

The model views Supernus Pharmaceuticals as a HOLD, balancing long-term product ramp-up in ADHD (Qelbree) against near-term margin compression and generic erosion of legacy drugs.

View the full interactive analysis